Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
National Journal of Andrology ; (12): 788-791, 2015.
Article in Chinese | WPRIM | ID: wpr-276019

ABSTRACT

<p><b>OBJECTIVE</b>To explore the antitumoral effect of indirubin on androgen-independent prostate cancer PC-3 cells and its possible mechanisms.</p><p><b>METHODS</b>We measured the inhibitory effect of indirubin on the proliferation of prostate cancer PC-3 cells using MTT assay, detected their cell cycles by flow cytometry, and determined the expressions of the cell cycle regulatory protein cyclin D1 and its related downstream gene c-myc by Western blot.</p><p><b>RESULTS</b>The viability of the PC-3 cells was significantly decreased by indirubin in a concentration-dependent manner, reduced to 52. 2% and 13. 6% at 5 and 10 µmol/L, respectively. The cell cycle of the PC-3 cells was markedly inhibited by indirubin at 5 µmol/L, with the cells remarkably increased in the G0 and G1 phases and decreased in the S and G2/M phases. Meanwhile, indirubin also inhibited the expressions of cyclin D1 and c-myc in the Wnt signaling pathway.</p><p><b>CONCLUSION</b>Indirubin can suppress the proliferation of androgen-independent prostate cancer PC-3 cells, which may be associated with its inhibitory effect on the cell cycle and Wnt signaling pathway.</p>


Subject(s)
Humans , Male , Antibiotics, Antineoplastic , Pharmacology , Cell Cycle , Cell Line, Tumor , Cell Proliferation , Cell Survival , Coloring Agents , Cyclin D1 , Metabolism , Dose-Response Relationship, Drug , Genes, myc , Indoles , Pharmacology , Prostatic Neoplasms, Castration-Resistant , Drug Therapy , Pathology , Proto-Oncogene Proteins c-myc , Metabolism , Tetrazolium Salts , Thiazoles
2.
National Journal of Andrology ; (12): 896-899, 2015.
Article in Chinese | WPRIM | ID: wpr-276000

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the feasibility and advantages of transurethral transumbilical laparoendoscopic single-site surgery (TU-LESS) for radical prostatectomy.</p><p><b>METHODS</b>Five patients with prostate cancer underwent TU-LESS for radical prostatectomy, with a four-channel single-port device inserted into a 2. 5 cm periumbilical incision and another placed through the urethra, followed by analysis of the perioperative data.</p><p><b>RESULTS</b>All the operations were successfully accomplished, with neither conversion to open surgery nor additional channel. The mean operation time, intraoperative blood loss, and postoperative hospital stay were 168 min, 120 ml, and 15 d, respectively. No severe perioperative complications were observed. TNM stage classification manifested T2cN0M0 in 2 cases and T2bN0M0 in the other 3. Postoperative pathology showed no negative surgical margins in any of the cases.</p><p><b>CONCLUSION</b>TU-LESS is safe and feasible for radical prostatectomy and can reduce the complication of low urinary tract surgery by single-site laparoendoscopy.</p>


Subject(s)
Humans , Male , Blood Loss, Surgical , Feasibility Studies , Laparoscopy , Length of Stay , Natural Orifice Endoscopic Surgery , Methods , Operative Time , Prostatectomy , Methods , Prostatic Neoplasms , General Surgery , Umbilicus , General Surgery , Urologic Surgical Procedures, Male , Methods
SELECTION OF CITATIONS
SEARCH DETAIL